Investment Summary

Andera Partners and EQT Life Sciences Invest In Amolyt Pharma

On September 16, 2021, private equity firm Andera Partners and growth capital firm EQT Life Sciences invested in life science company Amolyt Pharma

Investment Highlights
  • This is Andera Partners’ 23rd and EQT Life Sciences’ 25th transaction in the Life Science sector.
  • This is Andera Partners’ 60th and EQT Life Sciences’ 3rd transaction in France.
Investment Fate
  • Amolyt Pharma was sold to a publicly-traded strategic buyer in 2024 for 1.1B USD.

Investment Summary

Date 2021-09-16
Target Amolyt Pharma
Sector Life Science
Investor(s) Andera Partners
EQT Life Sciences
Deal Type Venture

Target

Amolyt Pharma

Ecully, France
Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 2

Investor

Andera Partners

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2001
PE ASSETS 3.7B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.


DEAL STATS #
Overall 91 of 106
Sector: Life Science M&A 23 of 27
Type: Venture M&A Deals 24 of 28
Country: France M&A 60 of 70
Year: 2021 M&A 9 of 11
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-09 Evommune

Los Altos, California, United States

Evommune is a biopharmaceutical company developing innovative therapies in the area of chronic inflammation, particularly in dermatological conditions. Evommune was founded in 2020 and is based in Los Altos, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-26 Exciva

Heidelberg, Germany

Exciva is a clinical biotech company developing a novel therapeutic compound for the treatment of behavioral and psychological symptoms in alzheimer’s patients. Exciva was founded in 2016 and is based in Heidelberg, Germany.

Buy -
Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 3.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.


DEAL STATS #
Overall 41 of 47
Sector: Life Science M&A 25 of 30
Type: Venture M&A Deals 35 of 39
Country: France M&A 3 of 4
Year: 2021 M&A 9 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-09 Evommune

Los Altos, California, United States

Evommune is a biopharmaceutical company developing innovative therapies in the area of chronic inflammation, particularly in dermatological conditions. Evommune was founded in 2020 and is based in Los Altos, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-22 Egle

Paris, France

Egle is a biotechnology company focused on developing first in class T-regulatory cell therapies based on Treg-starvers for oncology and autoimmune diseases. Egle was founded in 2020 and is based in Paris, France.

Buy -